Marker Therapeutics Inc (MRKR)

[dmj3430]

"TPIV 200 for TNBC (NCT02593227): "The data that we have is when we released the TPIV200 findings back in March." The whitepaper can be found HERE & the publication to AACR Clinical Cancer Research can be found HERE."

This response doesn't jive with the 10Q. They either lied when they submitted the last 10q or whomever wrote it didn't know what the hell he was talking about. The 10Q specifically stated that interim results would be available "Mid 2018"

Not good in either case.